Serum levels of β-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma

Oncology Reports

Volumn 26, Issue 4, 2011, Pages 825-831

  Zekri, Abdel Rahman N ^a   Bahnassy, Abeer A ^b   El Din, Hanaa M Alam ^a   Morsy, Heba M ^a   Shaarawy, Sabry ^a   Moharram, Nagia Z ^c   Daoud, Sayed S ^d  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL CANCER INSTITUTE   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

^d WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

catenin; Chronic hepatitis C; E cadherin; Hepatitis C virus genotype 4; Hepatocellular carcinoma; Serum markers

Indexed keywords

BETA CATENIN; GELATINASE A; INTERCELLULAR ADHESION MOLECULE 1; OSTEOPONTIN; UVOMORULIN; VASCULOTROPIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BETA CATENIN; CADHERINS; CARCINOMA, HEPATOCELLULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; OSTEOPONTIN; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 79960798528     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1355     Document Type: Article

References (40)

1. Nordenstedt H, White DL and El-Serag HB: Changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 42 (Suppl 3): S206-S214, 2010.
2. Bosch FX, Ribes J and Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 19: 271-285, 1999. (Pubitemid 29488770)
3. Cabibbo G and Craxi A: Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 14: 352-355, 2010.
4. El-Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750, 1999. (Pubitemid 29114292)
5. Lehman EM and Wilson ML: Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality. J Viral Hepatol 16: 650-658, 2009.
6. Lehman EM and Wilson ML: Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. Int J Cancer 124: 690-697, 2009.
7. Spangenberg HC, Thimme R and Blum HE: Serum markers of hepatocellular carcinoma. Semin Liver Dis 26: 385-390, 2006. (Pubitemid 44632929)
8. Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y and Omata M: Diagnostic accuracy of tumor markers for hepato-cellular carcinoma: a systematic review. Hepatol Int 2: 17-30, 2008. (Pubitemid 351250400)
9. Sherman M, Peltekian KM and Lee C: Screening for hepato-cellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 22: 432-438, 1995.
10. Di Bisceglie AM and Hoofnagle JH: Elevations in serum α-fetoprotein levels in patients with chronic hepatitis B. Cancer 64: 2117-2120, 1989. (Pubitemid 19280413)
11. Wright LM, Kreikemeier JT and Fimmel CJ: A concise review of serum markers for hepatocellular cancer. Cancer Detect Prev 31: 35-44, 2007. (Pubitemid 46367447)
12. Soyama A, Eguchi S, Takatsuki M, Kawashita Y, Hidaka M, Tokai H, Nagayoshi S, Mochizuki S, Matsumoto S, Mochizuki S S, Matsumoto S, Hamasaki K, Tajima Y and Kanematsu T: Significance of the serum level of soluble E-cadherin in patients with HCC. Hepatogastroenterology 55: 1390-1393, 2008.
13. Sun Y, Mi W, Cai J, Ying W, Liu F, Lu H, Qiano Y, Jia W, Bi X, Lu N, Liu S, Qian X and Zhao X: Quantitative proteomic signature of liver cancer cells: tissue transglutaminase-2 could be a novel protein candidate of human hepatocellular carcinoma. J Proteome Res 7: 3847-3859, 2008.
14. Yeh HC, Lin SM, Chen MF, Pan TL, Wang PW and Yeh CT: Evaluation of serum matrix metalloproteinase (MMP)-9 to MMP-2 ratio as a biomarker in hepatocellular carcinoma. Hepatogastroenterology 57: 98-102, 2010.
15. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR and Gores GJ: Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 100: 1385-1392, 2009.
16. Zhao L, Li T, Wang Y, Pan Y, Ning H, Hui X, Xie H, Wang J, Han Y, Liu Z and Fan D: Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract 62: 1056-1062, 2008. (Pubitemid 351793583)
17. Zulehner G, Mikula M, Schneller D, van Zijl F, Huber H, Sieghart W, Grasl-Kraupp B, Waldhör, Peck-Radosavijevic M, Beug H and Mikulits W: Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence. Am J Pathol 176: 472-481, 2010.
18. Zekri A, Alam El-Din HM, Bahnassy AA, El-Shehabi AM, El-Leethy H, Omar A and Khaled HM: TRUGENE sequencing versus INNO-LiPA for sub-genotyping of HCV genotype-4. J Med Virol 75: 412-420, 2005. (Pubitemid 40175906)
19. Zekri A, Hafez MM, Mohamed NI, Hassan ZK, El-Sayed MH, Khaled MM and Mansour T: Hepatitis B virus (HBV) genotypes in Egyptian pediatric cancer patients with acute and chronic active HBV infection. Virol J 4: 474-481, 2007.
20. Sun Y, Chua MS, Yang D, Tsalenko A, Peter BJ and So S S: Antibody arrarys identify potential diagnostic markers of hepatocellular carcinoma. Biomark Insights 3: 1-18, 2008.
21. Wong CM, Fan ST and Ng IO: Beta-catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 92: 136-145, 2001. (Pubitemid 32623050)
22. Inagawa S, Itabashi M, Adachi S, Kawamoto T, Hori M, Shimazaki J, Yoshimi F and Fukao K: Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 8: 450-456, 2002. (Pubitemid 34193964)
23. Kim Y, Sills RC and Houle CD: Overview of the molecular biology of hepatocellular neoplasms and hepatoblastomas of the mouse liver. Toxicol Pathol 33: 175-180, 2005. (Pubitemid 40216816)
24. Reed KR, Athineos D, Meniel VS, Wilkins JA, Ridgway RA, Burke ZD, Muncan V, Clarke AR and Sansom OJ: B-catenin deficiency, but not Myc deletion, suppresses the immediate phenotypes of APC loss in the liver. Proc Natl Acad Sci USA 105: 18919-18923, 2008.
25. Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES and Buendia MA: Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 155: 703-710, 1999. (Pubitemid 29426815)
26. Nakamura T, Hamada F, Ishidate T, Anai K, Kawahara K, Toyoshima K and Akiyama T: Axin, an inhibitor of the Wnt signaling pathway, interacts with beta-catenin, GSK-3beta and APC and reduces the beta-catenin level. Genes Cells 3: 395-403, 1998. (Pubitemid 28387083)
27. Park JY, Park WS, Nam SW, Kim SY, Lee SH, Yoo NJ, Lee JY and Park CK: Mutations of beta-catenin and AXIN 1 genes are a late event in human hepatocellular carcinogenesis. Liver Int 25: 70-76, 2005. (Pubitemid 40298247)
28. Zucman-Rossi J, Benhamouche S, Godard C, Boyault S, Grimber G, Balabaud C, Cunha AS, Bioulac-Sage P and Perret C: Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 26: 774-780, 2007. (Pubitemid 46204256)
29. Kuefer R, Hofer MD, Zorn CS, Engel O, Volkmer BG, Juarez-Brito MA, Eggel M, Gschwend JE, Rubin MA and Day ML: Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer. Br J Cancer 92: 2018-2023, 2005. (Pubitemid 40897424)
30. Pittard AJ, Galley HF and Webster NR: Soluble E-cadherin concentrations in patients with systemic inflammatory response syndrome and multiorgan dysfunction syndrome. Br J Anaesth 76: 629-631, 1996. (Pubitemid 26129534)
31. Moriyama M, Matsumura H, Shioda J, Aoki H, Nakamura H, Arakawa Y, Nirei K, Yamagami H, Kaneko M, Tanaka N and Arakawa Y: Measurement of human intercellular adhesion molecule 1 in the blood is useful for predicting the occurrence of hepatocellular carcinoma from chronic hepatitis C and liver cirrhosis. Intervirology 49: 327-338, 2006. (Pubitemid 44543598)
32. Shimizu Y, Minemura M, Tsukishiro T, Kashii Y, Miyamoto M, Nishimori H, Higuchi K and Watanabe A: Serum concentration of intercellular adhesion molecule-1 in patients with hepato-cellular carcinoma is a marker of the disease progression and prognosis. Hepatology 22: 525-531, 1995.
33. Kuyvenhoven JP, van Hoek B, Blom E, van Duijn W, Hanemaaijer R, Verheijen JH, Lamers CB and Verspaget HW: Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic liver diseases and hepatocellular carcinoma. Thromb Haemost 89: 718-725, 2003. (Pubitemid 36456969)
34. Lichtinghagen R, Huegel O, Seifert T, Haberkorn CI, Michels D, Flemming P, Bahr M and Boeker KH: Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem 46: 183-192, 2000. (Pubitemid 30104241)
35. Ebata M, Fukuda Y, Nakano I, Katano Y, Fujimoto N and Hayakawa T: Serum levels of tissue inhibitor of metallo-proteinases-2 and of precursor from a matrix metalloproteinase-2 in patients with liver disease. Liver 17: 293-299, 1997. (Pubitemid 28014678)
36. Huang W, Zhu G, Huang M, Lou G, Liu Y and Wang S: Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects. Clin Chim Acta 411: 675-678, 2010.
37. Kim J, Ki SS, Lee SD, Han CJ, Kim YC, Park SH, Cho SY, Hong YJ, Park HY, Lee M, Jung HH, Lee KH and Jeong SH: Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 101: 2051-2059, 2006. (Pubitemid 44337631)
38. Jinno K, Tanimizu M and Hyodo I: Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 33: 376-382, 1998. (Pubitemid 28263653)
39. Zhao J, Hu J, Cai J, Yang X and Yang Z: Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma. Chin Med J 116: 772-776, 2003. (Pubitemid 36701868)
40. Niu Q, Tang ZY, Ma ZC, Qin LX and Zhang LH: Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma. World J Gastroenterol 6: 565-568, 2000. (Pubitemid 30665270)